LGND:NASDAQ
Ligand Pharmaceuticals
297,20 $
arrow_upward
+0,09%(+0,26) 1Д
7 окт., 13:45:51 GMT-4 · USD
search
Все тикеры
| Тикер | Цена | Изменения | Динамика (%) |
|---|
insights_autoСоздание статистики для тикера LGND…
Открыть
293,63 $
Высокая
301,26 $
Низкая
293,63 $
Рын. кап.
5,92 млрд
Средн. объем
237,93 тыс.
Объем
92,25 тыс.
Коэффициент P/E
31,61
Макс. цена за 52 нед.
326,63 $
Мин. цена за 52 нед.
175,89 $
Прибыль на акцию
9,40 $
Бета
1,06
Акции в обращении
19,94 млн
Число сотрудников
47
Открыть
293,63 $
Высокая
301,26 $
Низкая
293,63 $
Рын. кап.
5,92 млрд
Средн. объем
237,93 тыс.
Объем
92,25 тыс.
Коэффициент P/E
31,61
Макс. цена за 52 нед.
326,63 $
Мин. цена за 52 нед.
175,89 $
Прибыль на акцию
9,40 $
Бета
1,06
Акции в обращении
19,94 млн
Число сотрудников
47
Новости
Из источников в интернете и от информационных партнеров
Benzinga
·
10 часов назад
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
AD HOC NEWS
·
13 часов назад
Ligand Pharmaceuticals stock fell 3.2 percent as insiders sold shares
AD HOC NEWS
·
3 дня назад
Ligand Pharmaceuticals stock reports stronger royalty growth after Q2 results
Профиль
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
О компании "Ligand Pharmaceuticals"
Генеральный директор-
Количество сотрудников47
Дата основаниясент. 1987
Штаб-квартираДжупитер, Флорида, Соединенные Штаты Америки
Сектор-
Сайтligand.com